Statistical flags indicate unusual patterns — not proof of fraud or wrongdoing. Read our methodology

Provider 1316909203

NPI: 1316909203Share
Active Billing Period:2018-012024-06(78 months)

Extreme procedure concentration — 100% of $10.3M billed through a single code

Total Paid

$10.3M

$10,270,787

Total Claims

2,548

Beneficiaries

1,798

1.4 claims/patient

Avg Cost/Claim

$4K

Monthly Spending Trend

Yearly Spending

2018
$2.8M
-25%
2019
$2.1M
-33%
2020
$1.4M
-8%
2021
$1.3M
-24%
2022
$964K
+30%
2023
$1.2M
-55%
2024
$567K

Procedure Breakdown

Cost per claim compared to national benchmarks

This provider bills for 1 distinct procedure code. The top code (Q5003 (Injection, infliximab-dyyb, biosimilar, 10 mg)) accounts for 100% of total spending.

Q5003Top 25%

Injection, infliximab-dyyb, biosimilar, 10 mg

$10.3M

2,548 claims · 100.0%

Your Cost: $4,030.92/claim|Median: $177.99
22.6× median